UPJOHN HOPES TO INTRODUCE MOTRIN IB SINUS BY THE END OF 1993
This article was originally published in The Tan Sheet
Executive Summary
UPJOHN HOPES TO INTRODUCE MOTRIN IB SINUS BY THE END OF 1993 pending approval from FDA. Motrin IB Sinus would be the first symptom-specific product in the Motrin IB line. Upjohn currently markets Motrin IB (ibuprofen) caplets and tablets. The company is understood to be seeking a number of indications for Motrin IB Sinus including pain relief, fever reduction and nasal decongestion. The product will contain ibuprofen 200 mg and pseudoephedrine 30 mg. Other products on the market with the ibuprofen/pseudoephedrine combination include Whitehall's Advil Cold & Sinus and Dristan Sinus and Robins' Dimetapp Sinus. Upjohn anticipates that Motrin IB Sinus, if cleared, will be offered in both coated caplets and coated tablets. The ad agency of record for the existing Motrin IB line is Southfield, Mich.- based W. B. Doner & Company.